Atacand For CHF: Can AstraZeneca CHARM FDA Into ACE Combo Approval?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca’s upcoming Atacand sNDA for use in heart failure will likely raise issues about conflicting data on another agent in the same class.
You may also be interested in...
AstraZeneca Submits Atacand For Heart Failure; First ARB To Affect Mortality
AstraZeneca’s Atacand supplemental NDA filing for a chronic heart failure claim is based on the first heart failure study to demonstrate a clear mortality benefit with an angiotensin-II receptor blocker.
Novartis Diovan Heart Failure Indication Covers 1.2-2.5 Million Patients
Novartis will be targeting 1.2 mil. to 2.5 mil. patients with the August 14 approval of Diovan for "treatment of heart failure (NYHA class II-IV) in patients who are intolerant of angiotensin converting enzyme inhibitors."
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011